G1 Therapeutics Stock Forecast, Price & News

+0.25 (+1.66 %)
(As of 09/23/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume542,952 shs
Average Volume1.21 million shs
Market Capitalization$648.77 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

G1 Therapeutics logo

About G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.04 out of 5 stars

Medical Sector

518th out of 1,351 stocks

Pharmaceutical Preparations Industry

254th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

Is G1 Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than G1 Therapeutics?

Wall Street analysts have given G1 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but G1 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for G1 Therapeutics

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its earnings results on Wednesday, August, 4th. The company reported ($0.94) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.02. The firm had revenue of $6.60 million for the quarter, compared to the consensus estimate of $2.70 million. G1 Therapeutics had a negative net margin of 160.84% and a negative trailing twelve-month return on equity of 49.38%.
View G1 Therapeutics' earnings history

How has G1 Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GTHX shares have increased by 5.7% and is now trading at $15.32.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GTHX?

5 brokers have issued 12-month price objectives for G1 Therapeutics' stock. Their forecasts range from $21.00 to $82.00. On average, they expect G1 Therapeutics' share price to reach $53.00 in the next twelve months. This suggests a possible upside of 246.0% from the stock's current price.
View analysts' price targets for G1 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:
  • Jack Bailey, President, Chief Executive Officer & Director
  • Terry L. Murdock, Chief Operating Officer
  • Jennifer K. Moses, Chief Financial Officer
  • Rajesh K. Malik, Chief Medical Officer (LinkedIn Profile)
  • David D. Elks, Head-Information Technology

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.63%), State Street Corp (6.54%), Vanguard Group Inc. (5.91%), JPMorgan Chase & Co. (4.43%), Dimensional Fund Advisors LP (2.53%) and Fisher Asset Management LLC (2.17%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, Mark A Velleca, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics

Which major investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Susquehanna International Group LLP, Goldman Sachs Group Inc., MPM Oncology Impact Management LP, Burrage Capital Management LLC, PDT Partners LLC, Los Angeles Capital Management LLC, and Rafferty Asset Management LLC. Company insiders that have sold G1 Therapeutics company stock in the last year include Mark A Velleca, Rajesh Malik, and Seth Rudnick.
View insider buying and selling activity for G1 Therapeutics
or view top insider-selling stocks.

Which major investors are buying G1 Therapeutics stock?

GTHX stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Morgan Stanley, Morgan Stanley, Point72 Asset Management L.P., Tekla Capital Management LLC, Dimensional Fund Advisors LP, Nuveen Asset Management LLC, and BlackRock Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $15.32.

How much money does G1 Therapeutics make?

G1 Therapeutics has a market capitalization of $648.77 million and generates $45.28 million in revenue each year. The company earns $-99,250,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis.

How many employees does G1 Therapeutics have?

G1 Therapeutics employs 122 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is

Where are G1 Therapeutics' headquarters?

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at (919) 213-9835 or via email at [email protected].

This page was last updated on 9/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.